Fighting mucopolysaccharidosis type I, a rare disease, by reprogramming B-cells - Beyond Biotech - the podcast from Labiotech

Fighting mucopolysaccharidosis type I, a rare disease, by reprogramming B-cells - Beyond Biotech - the podcast from Labiotech

There are cell therapies, gene therapies, and biologics – and then there is Immusoft. Immusoft sits at the nexus point of some of the most innovative approaches in biopharma, and their Immune System Programming platform is unique in its capacity to address the rare disease, MPS I. This ...